Biotech Due Diligence Globalization 
Alpha Sense BI
MAY 5, 2023
After three volatile years, rife with challenging macroeconomic conditions — from a global pandemic and wars to far-reaching supply chain issues — the M&A space has its fair share of ups and downs. Many pharma companies with expiring patents are on the hunt to acquire biotech companies to address gaps in drug pipelines.
Alpha Sense BI
APRIL 29, 2024
Traditional due diligence for start-up investors has historically been riddled with inefficiencies—tying up resources to sort through countless documents and copious amounts of data, and manually crafting market comparisons and performance. There is no doubt that generative AI has emerged as a powerful tool in the investment space.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Alpha Sense BI
MARCH 13, 2024
According to PwC’s Annual Global CEO survey, 54% of healthcare industry CEOs intend to make at least one acquisition in the next three years. According to an outlook published by PwC , “large-cap pharma companies are expected to continue pursuing mid-sized biotech companies to fill pipeline gaps in the face of impending patent cliffs.
Alpha Sense BI
APRIL 19, 2024
On the other hand, 2022 and 2023 brought mass layoffs , falling market capitalizations, and a weakening of global tech spending. In fact, projections for the global spatial computing market are valued at $269.8 In any case, this technology is one to watch—the global computing market is set to grow at a CAGR of 28.8%
Engage3
MAY 19, 2022
He has a wealth of cross-industry experience in accelerating companies’ growth and raising capital, having spent more than fifteen years in SaaS companies as CFO and COO in industries as varied as manufacturing and biotech. He received his Bachelor of Arts in Economics and Political Science from Williams College. Bryan Courtney- Bennett Sr.
Expert insights. Personalized for you.
97 
Let's personalize your content